Citations

Clear

6273 citation(s) found for "To, Andrew".

Glucose homeostasis after simultaneous pancreas and kidney transplantation: a comparison of subjects with C‐peptide‐positive non‐type 1 diabetes mellitus and type 1 diabetes mellitus
Chakkera, Harini A. , Kudva, Yogish C. , Chang, Yu‐Hui H., Heilman, Raymond L. , Singer, Andrew L., Mathur, Amit K. , Hewitt, Winston R. , Khamash, Hasan , Huskey, Janna L. , Katariya, Nitin , Moss, Adyr A. , Behmen, Senaida, Reddy, Kunam S. , Khamash, Hasan A, Katariya, Nitin N , Chakkera, Harini A

Mayo Clinic

Clinical Transplantation | October 20, 2015 | Volume: 30 | Issue: 1 | Pages: 52-59

10.1111/ctr.12658 | PMID 26485408 Get It

AbstractBackgroundWhile simultaneous pancreas kidney transplant (SPKTx) is a therapeutic option for patients with type 1 diabetes (T1DM) and renal failure, few centers offer SPKTx to “select” non‐T1DM patients. To address concerns that existing insulin resistance may limit the benefits of the pancreas allograft among non‐T1DM, we compared several indices of glucose homeostasis, in “select” non‐T1DM and T1DM patients who received SPKTx.MethodsCriteria for “select” non‐T1DM included the following: positive C‐peptide, BMI <30 kg/m2, treatment with oral agents before insulin initiation, and insulin at <1 unit/kg/d. We compared several indices of glucose homeostasis within 1 yr post‐SPKTx among seven “select” patients with non‐T1DM and nine patients with T1DM with similar age, BMI, and immunosuppression. Measurements of insulin resistance included the following: homeostatic model, insulin sensitivity index, and insulin–glucose ratio; insulin secretion measures included the following: corrected insulin response.ResultsNon‐T1DM had similar pre‐transplant metabolic (fasting glucose, HbA1c, blood pressure, and lipid) parameters to the T1DM cohort. There were no significant differences in the various measures of insulin resistance and secretion between T1DM and “select” non‐T1DM patients.ConclusionOur results suggest SPKTx should be considered in the therapeutic armamentarium among carefully select non‐T1DM with features of minimal insulin resistance; however, a larger cohort with longer follow‐up is needed to confirm our results.
Defining the Role of Dexmedetomidine in the Prevention of Delirium in the Intensive Care Unit
Nelson, Sarah , Muzyk, Andrew J. , Bucklin, Mason H., Brudney, Scott, Gagliardi, Jane P.

Mayo Clinic

BioMed Research International | October 19, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-7

10.1155/2015/635737 | PMID 26576429 Get It

Dexmedetomidine is a highly selectiveα2agonist used as a sedative agent. It also provides anxiolysis and sympatholysis without significant respiratory compromise or delirium. We conducted a systematic review to examine whether sedation of patients in the intensive care unit (ICU) with dexmedetomidine was associated with a lower incidence of delirium as compared to other nondexmedetomidine sedation strategies. A search of PUBMED, EMBASE, and the Cochrane Database of Systematic Reviews yielded only three trials from 1966 through April 2015 that met our predefined inclusion criteria and assessed dexmedetomidine and outcomes of delirium as their primary endpoint. The studies varied in regard to population, comparator sedation regimen, delirium outcome measure, and dexmedetomidine dosing. All trials are limited by design issues that limit our ability definitively to conclude that dexmedetomidine prevents delirium. Evidence does suggest that dexmedetomidine may allow for avoidance of deep sedation and use of benzodiazepines, factors both observed to increase the risk for developing delirium. Our assessment of currently published literature highlights the need for ongoing research to better delineate the role of dexmedetomidine for delirium prevention.
Painful Ejaculation with Cyclobenzaprine: A Case Report and Literature Review
Kraus, Molly B. , Wie, Christopher , Gorlin, Andrew , Wisenbaugh, Eric S., Rosenfeld, David M. , Wie, Christopher S, Gorlin, Andrew W, Kraus, Molly B

Mayo Clinic

Sexual Medicine | October 19, 2015 | Volume: 3 | Issue: 4 | Pages: 343-345

10.1002/sm2.93 | PMID 26797071 Get It

Abstract Introduction Sexual dysfunction is a well-known side effect of antidepressants. Painful ejaculation is a rare side effect that has been reported with the use of some psychiatric drugs such as triclyclic antidepressants. Cyclobenzaprine is a muscle relaxant that is structurally similar to tricyclic antidepressants. It is the most commonly prescribed muscle relaxant in the United States and accounts for 18% of all prescriptions written for chronic back pain. Methods A 55-year-old man was referred to our pain medicine clinic for evaluation and treatment of pain with ejaculation. Main outcome Measure The main outcome measure was to review the current published literature and case reports on painful ejaculation from medication use, in particular tricyclic antidepressants. Results After discontinuation of cyclobenzaprine, our patient's sexual dysfunction resolved. This result was consistent with the literature reviewed on the topic. Conclusion Painful ejaculation is likely an underreported side effect of tricyclic antidepressants and cyclobenzaprine use. Fortunately, these symptoms are reversible and discontinuation of these medications is typically an effective cure.
The fate of cranial neuropathy after flow diversion for carotid aneurysms
Brown, Benjamin L. , Miller, David A. , Brasiliense, Leonardo B.C. , Ringer, Andrew J. , Sauvageau, Eric , Powers, Ciarán J. , Hoit, Daniel , Siddiqui, Adnan H. , Hopkins, L. Nelson , Rodríguez‐Mercado, Rafael, Veznedaroglu, Erol, Binning, Mandy J., Aguilar‐Salinas, Pedro , Boulos, Alan S. , Lopes, Demetrius K. , Tawk, Rabih G. , Arthur, Adam Stephen , Snyder, Kenneth V. , Levy, Elad I. , Cuellar, Hugo , Mocco, J , Yamamoto, Junichi , Hanel, Ricardó A. , Siddiqui, Adnan H

Mayo Clinic

Journal of Neurosurgery | October 16, 2015 | Volume: 124 | Issue: 4 | Pages: 1107-1113

10.3171/2015.4.jns142790 | PMID 26473786 Get It

OBJECT The authors sought to determine whether flow diversion with the Pipeline Embolization Device (PED) can approximate microsurgical decompression in restoring function after cranial neuropathy following carotid artery aneurysms. METHODS This multiinstitutional retrospective study involved 45 patients treated with PED across the United States. All patients included presented between November 2009 and October 2013 with cranial neuropathy (cranial nerves [CNs] II, III, IV, and VI) due to intracranial aneurysm. Outcome analysis included clinical and procedural variables at the time of treatment as well as at the latest clinical and radiographic follow-up. RESULTS Twenty-six aneurysms (57.8%) were located in the cavernous segment, while 6 (13.3%) were in the clinoid segment, and 13 (28.9%) were in the ophthalmic segment of the internal carotid artery. The average aneurysm size was 18.6 mm (range 4–35 mm), and the average number of flow diverters placed per patient was 1.2. Thirty-eight patients had available information regarding duration of cranial neuropathy prior to treatment. Eleven patients (28.9%) were treated within 1 month of symptom onset, while 27 (71.1%) were treated after 1 month of symptoms. The overall rate of cranial neuropathy improvement for all patients was 66.7%. The CN deficits resolved in 19 patients (42.2%), improved in 11 (24.4%), were unchanged in 14 (31.1%), and worsened in 1 (2.2%). Overtime, the rate of cranial neuropathy improvement was 33.3% (15/45), 68.8% (22/32), and 81.0% (17/21) at less than 6, 6, and 12 months, respectively. At last follow-up, 60% of patients in the isolated CN II group had improvement, while in the CN III, IV, or VI group, 85.7% had improved. Moreover, 100% (11/11) of patients experienced improvement if they were treated within 1 month of symptom onset, whereas 44.4% (12/27) experienced improvement if they treated after 1 month of symptom onset; 70.4% (19/27) of those with partial deficits improved compared with 30% (3/10) of those with complete deficits. CONCLUSIONS Cranial neuropathy caused by cerebral aneurysm responds similarly when the aneurysm is treated with the PED compared with open surgery and coil embolization. Lower morbidity and higher occlusion rates obtained with the PED may suggest it as treatment of choice for some of these lesions. Time to treatment is an important consideration regardless of treatment modality.
Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease
Hwang, Young‐Hwan , Conklin, John , Roslin, Nicole M. , Liu, Jannel , He, Ning , Wang, Kairong , Sundsbak, Jamie L., Heyer, Christina M., Haider, Masoom A. , Paterson, Andrew D. , Harris, Peter C. , Pei, York , Chan, Winnie , Harris, Peter C , Paterson, Andrew

Mayo Clinic

Journal of the American Society of Nephrology | October 9, 2015 | Volume: 27 | Issue: 6 | Pages: 1861-1868

10.1681/asn.2015060648 | PMID 26453610 Get It

Renal disease variability in autosomal dominant polycystic kidney disease (ADPKD) is strongly influenced by the gene locus ( PKD1 versus PKD2 ). Recent studies identified nontruncating PKD1 mutations in approximately 30% of patients who underwent comprehensive mutation screening, but the clinical significance of these mutations is not well defined. We examined the genotype-renal function correlation in a prospective cohort of 220 unrelated ADPKD families ascertained through probands with serum creatinine ≤1.4 mg/dl at recruitment. We screened these families for PKD1 and PKD2 mutations and reviewed the clinical outcomes of the probands and affected family members. Height–adjusted total kidney volume (htTKV) was obtained in 161 affected subjects. Multivariate Cox proportional hazard modeling for renal and patient survival was performed in 707 affected probands and family members. Overall, we identified pathogenic mutations in 84.5% of our families, in which the prevalence of PKD1 truncating, PKD1 in–frame insertion/deletion, PKD1 nontruncating, and PKD2 mutations was 38.3%, 4.3%, 27.1%, and 30.3%, respectively. Compared with patients with PKD1 truncating mutations, patients with PKD1 in–frame insertion/deletion, PKD1 nontruncating, or PKD2 mutations have smaller htTKV and reduced risks (hazard ratio [95% confidence interval]) of ESRD (0.35 [0.14 to 0.91], 0.10 [0.05 to 0.18], and 0.03 [0.01 to 0.05], respectively) and death (0.31 [0.11 to 0.87], 0.20 [0.11 to 0.38], and 0.18 [0.11 to 0.31], respectively). Refined genotype-renal disease correlation coupled with targeted next generation sequencing of PKD1 and PKD2 may provide useful clinical prognostication for ADPKD.
Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation
Hendifar, Andrew , Shroff, Rachna T. , Leichman, Lawrence, Epelbaum, Ron, Geva, Ravit , Kim, George , Wolff, Robert A. , Allen, Andrew R., Giordano, Heidi, Raponi, Mitch , Isaacson, Jeff, Rolfe, Lindsey, Vonderheide, Robert H. , Domchek, Susan M. , McWilliams, Robert R. , Alberts, Steven R. , Isaacson, Jeffrey D., Biankin, Andrew V.

Mayo Clinic

Cancer Research | October 5, 2015 | Volume: 75 | Issue: 13_Supplement | Pages: B102-B102

10.1158/1538-7445.panca2014-b102 Get It

Abstract Background: Despite the recent progress made with front-line treatment for advanced pancreatic cancer (PC), most patients (pts) will either relapse or be refractory to treatment. Others may not even be eligible due to the toxicity profile of the available options or due to clinical deterioration. Once the disease progresses following front-line treatment, there is no accepted standard of care. Treatment options are clearly needed for patients with refractory disease. Approximately 5% of unselected PC pts, 10% of PC patients of Ashkenazi Jewish descent, and up to 19% of familial PC cases, harbor a germline BRCA mutation. Though less well characterized to date, somatic BRCA mutations also appear to play a significant role in PC. Clinical data have shown that pts with BRCA-mutant (BRCAmut) tumors, including those with PC, respond to treatment with a PARP inhibitor (PARPi). Early data suggest that other genomic characteristics may be surrogate biomarkers of homologous recombination deficiency (HRD) and define a larger group of responders than just BRCA mutation(s) alone. Rucaparib, an oral PARPi, is being developed for treatment of cancers associated with HRD due to a BRCA mutation or other homologous recombination pathway defect. Rucaparib has a desirable PK profile, is well tolerated, and has demonstrated clinical activity (RECIST and/or CA-125 responses) in patients with BRCAmut pancreatic, ovarian, or breast cancer in an ongoing Phase 1/2 study (NCT01482715). Three studies are currently ongoing in ovarian cancer and a trial in BRCAmut pancreatic cancer is now planned. The clinical activity of PARPi, including rucaparib, in BRCAmut PC, combined with the paucity of active 2nd-line therapies, support evaluation of rucaparib in PC pts with a BRCA mutation. Methods: Study CO-338-023 (NCT02042378) is a single-arm, open-label Phase 2 trial of continuous monotherapy rucaparib in up to 100 pts with pancreatic ductal adenocarcinoma (or related subtype) who are known to harbor a deleterious BRCA mutation (germline or somatic). Pts must have received at least 1, but no more than 2, prior regimens for locally advanced or metastatic disease and have relapsed / progressive disease confirmed by radiologic assessment, or are no longer able to tolerate chemotherapy due to toxicity, and radiologic assessment confirms stable or progressive disease. Other key inclusion criteria include measurable disease, ECOG Performance Status 0 or 1, and adequate organ function. Pts with endocrine tumors or who received prior PARPi treatment are excluded. Pts will take 600 mg BID rucaparib continuously and be evaluated for safety every 2–4 wks, disease status (CT scans, CA19–9) every 4–8 wks until disease progression, and then for survival every 4 wks. Blood and archival tumor tissue (if available) will be collected from all pts. The primary endpoint is ORR by RECIST v1.1. Key secondary endpoints include duration of response, PFS, OS, and safety. Exploratory analyses include gene sequence and structural rearrangements of tumor DNA and evaluation of circulating tumor DNA. A group sequential interim monitoring plan will be implemented to stop the study early for either superior efficacy or futility. Interim analyses will occur after every 10th patient enrolled has sufficient disease assessment data available. If robust activity is observed in the BRCAmut PC population, the trial may be broadened to include PC pts with HRD due to other than a BRCA mutation. The trial will be open to enrollment at clinical sites in the US and Israel in 2Q 2014. Citation Format: Susan M. Domchek, Robert McWilliams, Andrew Hendifar, Rachna T. Shroff, Lawrence Leichman, Ron Epelbaum, Ravit Geva, George Kim, Steven R. Alberts, Robert A. Wolff, Andrew Allen, Heidi Giordano, Mitch Raponi, Jeff Isaacson, Lindsey Rolfe, Andrew Biankin, Robert H. Vonderheide. A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr B102.
Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures
Flanagan, Eoin P. , McKeon, Andrew , Watson, Robert E. , Klein, Christopher J. , Lowe, Val J. , Ahlskog, J. Eric , Shin, Cheolsu, Laughlin, Ruple S. , Pittock, Sean J. , Kotsenas, Amy L. , Boes, Christopher J. , Crum, Brian A. , Pittock, S J , Britton, Jeffrey W. , Boeve, Bradley F. , Flanagan, E P , Klein, Christopher J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | October 2, 2015 | Volume: 2 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000161 | PMID 26468474 Get It

First Steps toward Harmonization of LC-MS/MS Thyroglobulin Assays
Netzel, Brian C., Grant, Russell P. , Hoofnagle, Andrew N. , Rockwood, Alan L. , Shuford, Christopher M. , Grebe, Stefan K., Grebe, Stefan K G

Mayo Clinic

Clinical Chemistry | October 1, 2015 | Volume: 62 | Issue: 1 | Pages: 297-299

10.1373/clinchem.2015.245266 | PMID 26430076 Get It

Recurrent duplications of 17q12 associated with variable phenotypes
Mitchell, Elyse, Douglas, Andrew G. L. , Kjaegaard, Susanne, Callewaert, Bert , Janssens, Sandra , Yuen, Amy Lawson, Skinner, Cindy , Failla, Pinella , Alberti, A , Avola, Emanuela , Fichera, Marco , Kibæk, Maria, Digilio, M. Cristina , Hannibal, Mark , Hollander, Nicolette S. den , Bizzarri, Veronica, Renieri, Alessandra , Mencarelli, Maria Antonietta , Fitzgerald, Tomas , Piazzolla, Serena, Oudenhove, Elke Van , Romano, Corrado , Schwartz, Charles E. , Rajan, Diana, Crolla, John A., Carter, Nigel, Hodge, Jennelle C. , Vanlander, Arnaud Vincent , Eichler, Evan E , Slavotinek, Anne , Escobar, Luis Fernando , Mefford, Heather C. , Callewaert, Bert , Renieri, Alessandra

Mayo Clinic

American Journal of Medical Genetics Part A | September 30, 2015 | Volume: 167 | Issue: 12 | Pages: 3038-3045

10.1002/ajmg.a.37351 | PMID 26420380 Get It

The ability to identify the clinical nature of the recurrent duplication of chromosome 17q12 has been limited by its rarity and the diverse range of phenotypes associated with this genomic change. In order to further define the clinical features of affected patients, detailed clinical information was collected in the largest series to date (30 patients and 2 of their siblings) through a multi‐institutional collaborative effort. The majority of patients presented with developmental delays varying from mild to severe. Though dysmorphic features were commonly reported, patients do not have consistent and recognizable features. Cardiac, ophthalmologic, growth, behavioral, and other abnormalities were each present in a subset of patients. The newly associated features potentially resulting from 17q12 duplication include height and weight above the 95th percentile, cataracts, microphthalmia, coloboma, astigmatism, tracheomalacia, cutaneous mosaicism, pectus excavatum, scoliosis, hypermobility, hypospadias, diverticulum of Kommerell, pyloric stenosis, and pseudohypoparathryoidism. The majority of duplications were inherited with some carrier parents reporting learning disabilities or microcephaly. We identified additional, potentially contributory copy number changes in a subset of patients, including one patient each with 16p11.2 deletion and 15q13.3 deletion. Our data further define and expand the clinical spectrum associated with duplications of 17q12 and provide support for the role of genomic modifiers contributing to phenotypic variability. © 2015 Wiley Periodicals, Inc.
A functional variant in HOXA11-AS , a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer
Richards, Edward J., Permuth‐Wey, Jennifer, Li, Yajuan , Coppola, Domenico , Reid, Brett M. , Lin, Hui‐Yi , Teer, Jamie K. , Birrer, Michael J. , Lawrenson, Kate , Monteiro, Álvaro N.A. , Schildkraut, Joellen M. , Goode, Ellen L. , Gayther, Simon A. , Sellers, Thomas A. , Cheng, Jin Q. , Chen, Y. Ann , Berchuck, Andrew , Lawrenson, Kate , Monteiro, Alvaro N , Lin, Hui-Yi

Mayo Clinic

Oncotarget | September 29, 2015 | Volume: 6 | Issue: 33 | Pages: 34745-34757

10.18632/oncotarget.5784 | PMID 26430965 Get It